Cargando…
Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era
RATIONALE & OBJECTIVE: Since the change in erythropoiesis-stimulating agent (ESA) labeling and bundling of dialysis services in the United States, few studies have addressed the clinical importance of ESA hyporesponsiveness and none have considered health care resource use in this population. We...
Autores principales: | Cizman, Borut, Smith, Helen T., Camejo, Rodrigo Refoios, Casillas, Linda, Dhillon, Harjeet, Mu, Fan, Wu, Eric, Xie, Jipan, Zuckerman, Peter, Coyne, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568064/ https://www.ncbi.nlm.nih.gov/pubmed/33089137 http://dx.doi.org/10.1016/j.xkme.2020.06.008 |
Ejemplares similares
-
Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)
por: Macdougall, Iain C., et al.
Publicado: (2023) -
Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020) -
Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020) -
An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects
por: Cizman, Borut, et al.
Publicado: (2018) -
Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)